Search Articles
Filter Articles
Open filtersClose filters
Sections
- All (3,567 articles)
- Pharma Events (45 articles)
- For Recruiters (261 articles)
- Careers Events (7 articles)
- Partners (3 articles)
- News (2,970 articles)
- Careers Advice (285 articles)
- Company Focus (186 articles)
- Company Career Hubs (1 article)
- Pharma Training (7 articles)
- 25 Years of PharmiWeb (13 articles)
- DE&I (2 articles)
Found 3,567 articles
WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions
- 23 Sep 2024
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the World Health Organization (WHO) has included dual-stain cytology testing in its cervical cancer prevention guideline.1
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
- 23 Sep 2024
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies’ Omicron KP.2-adapted monovalent COVID-19 vaccine (COMIRNATY ® KP.2) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.
Fasenra recommended for approval in the EU by CHMP for the treatment of eosinophilic granulomatosis with polyangiitis
- 23 Sep 2024
AstraZeneca’s Fasenra (benralizumab) has been recommended for approval in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).
FluMist approved for self-administration in the US
- 23 Sep 2024
FluMist has been approved in the US as the only self-administered influenza vaccine. FluMist, a needle-free nasal spray, was approved to be self-administered by adults up to 49 years of age or administered by a parent/caregiver to individuals 2-17 years of age.1
Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
- 23 Sep 2024
High-level results from the TROPION-Breast01 Phase III trial of datopotamab deruxtecan (Dato-DXd) compared to investigator’s choice of chemotherapy, which previously met the dual primary endpoint of progression-free survival (PFS), did not achieve statistical significance in the final overall survival (OS) analysis.
-
Just – Evotec Biologics opens cutting-edge biologics facility - J.POD® Toulouse, France (EU)
- 23 Sep 2024
Just – Evotec Biologics, the biologics segment of Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO), today celebrated the Grand Opening of its J.POD® biologics development and manufacturing facility located on Evotec’s Campus Curie in Toulouse, France.
What’s New in Clinical Research This Week?
- 20 Sep 2024
Here’s a round-up of some of the top news in clinical research this week!
IQVIA AI Solution Receives 2024 Frost & Sullivan Global Customer Value Leadership Award
- 20 Sep 2024
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced that Frost & Sullivan, a leading independent research and consulting firm, has awarded IQVIA with the 2024 Global Customer Value Leadership Award for excellence in the global artificial intelligence (AI) quality and regulatory solutions space for the healthcare industry.
Novo Nordisk A/S: Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function
- 20 Sep 2024
Wegovy® (semaglutide 2.4 mg) is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise function in people with obesity-related heart failure with preserved ejection fraction (HFpEF).
Renovos Biologics strengthens its Board’s US expertise with appointment of Lisa Ferrara, Ph.D., as a Non-Executive Director
- 19 Sep 2024
The appointment of Dr Ferrara, who has extensive experience developing new orthopaedic devices in the USA and obtaining regulatory approval for them, comes as Renovos presses ahead with development of its lead product RENOVITE® BMP-2, a next-generation precision drugs carrier.
10 Reasons Why Your Job Adverts Aren’t Performing
- 19 Sep 2024
There are many reasons why your job adverts might not be performing as well as you expected, and not all of them will be in your control. However, most factors affecting this performance are in your control and should be reviewed and improved on a regular basis.
Thermo Fisher Scientific Announces Expansion of Bioanalytical Laboratory Services in Europe
- 19 Sep 2024
The PPD™ clinical research business of Thermo Fisher Scientific, the world leader in serving science, announced today the expansion of its global laboratory services with a new bioanalytical lab in GoCo Health Innovation City in Gothenburg, Sweden, that will serve pharmaceutical and biotech customers with advanced laboratory services and leading-edge instrumentation across all phases of pharmaceutical development to help deliver life-changing medicines to patients worldwide.
Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
- 19 Sep 2024
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced updated data, including median progression-free survival (mPFS) and overall survival (OS) findings, from the Phase 2 trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in combination with chemotherapy as first-line treatment for patients with HER2-expressing advanced or metastatic gastroesophageal adenocarcinoma (mGEA).
Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships To Further Drive Health Impact in 93 Countries
- 19 Sep 2024
Takeda (TSE:4502/NYSE: TAK) today committed JPY4.6 billion (Approx. USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to improving health systems resiliency in low and middle-income countries around the world.
Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
- 19 Sep 2024
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results of the phase III CENTERSTONE study of Xofluza® (baloxavir marboxil), an antiviral, showing a reduction in the transmission of influenza viruses.
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
- 19 Sep 2024
Bristol Myers Squibb (NYSE: BMY) today announced new data from the Phase 3 DAYBREAK trial demonstrating that decreased rates of brain volume loss were sustained in the open-label extension (OLE) for patients treated with Zeposia (ozanimod) for relapsing forms of multiple sclerosis.
Stryker completes acquisition of care.ai
- 19 Sep 2024
Stryker (NYSE: SYK) announced that it has completed the previously announced acquisition of care.ai, a privately held company specializing in delivering AI-assisted virtual care workflows, smart room technology and ambient intelligence solutions.
New Survey from Abbott Finds Epidemiologists Believe Viral and Mosquito-Borne Pathogens are Priority Concerns for Disease Outbreaks
- 18 Sep 2024
Abbott announced the findings of a new survey among leading infectious disease experts around the world on the state of pandemic preparedness and found that while most agree that preparation has improved since the COVID-19 pandemic, respondents say significant gaps remain in building surveillance programs to identify emerging pathogens, public health funding and having adequate testing infrastructure capabilities.1
Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
- 18 Sep 2024
Moderna Inc (Nasdaq:MRNA) today announced that Health Canada has authorized its updated COVID-19 vaccine, SPIKEVAX® KP.2 variant, to help prevent COVID-19 in individuals six months of age and older. Moderna's updated COVID-19 vaccine targets the KP.2 sub-lineage of SARS-CoV-2.
New Immuno-Oncology Research Team in Partnership with Ono Pharmaceutical Starts at BioMed X Institute
- 18 Sep 2024
BioMed X, a German biomedical research institute, announced the start of a new research team at the BioMed X Institute in Heidelberg, Germany, the institute’s first joint research project with the Japanese company Ono Pharmaceutical Co., Ltd.
